BMS reports 2% rise in total revenue in Q2 2022
Revenues grew 12% to $8.3bn in the US for the three months ended on 30 June.
Dermatology
Latest in
Dermatology
Quoin and Endo sign supply deal for QRX003 in Canada
Under the supply deal, Quoin is entitled for manufacturing and supplying QRX003 to Endo.
Health Canada to review Arcutis’ roflumilast cream NDS for plaque psoriasis
The NDS submission is based on positive findings from the Phase III programme and two long-term trials of roflumilast cream…
Alopecia: Can new treatments pass the innovation and safety bar?
Despite a safety disclosure for one of the two anti-baldness assets on the market, demand for new treatments remains strong.
By
Vitiligo: all eyes on further Phase III data for Incyte’s ruxolitinib at AAD
With the FDA calling for more data on the JAK inhibitor in vitiligo, Incyte’s presentation is one to look out…
By
Quoin expands distribution deal with ER-Kim for Netherton Syndrome therapy
Through the deal extension, ER-Kim gained exclusive rights to commercialise QRX003 in six additional countries.
Pfizer signs agreement to acquire Arena Pharmaceuticals for $6.7bn
Arena’s portfolio includes several candidates in gastroenterology, dermatology and cardiology.
Impending regulatory approvals in atopic dermatitis (AD)
The availability of new atopic dermatitis therapies in the US and Europe has been affected by differences in regulatory policy.
By